Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
SkinHealth Systems Q1 2026 Earnings Call - EBITDA Surges While Device Sales Stall and Full-Year Revenue Cut
SkinHealth Systems reported a sharp divergence in Q1 2026 results. Adjusted EBITDA surged 17% year-over-year to $8.5 million, beating guidance by a wide margin, as operational discipline and higher av...
- Adjusted EBITDA reached $8.5 million, up 17% year-over-year and well above the high end of guidance ($3.5 million to $5.5 million), driven by gross margin expansion to 72.2% and disciplined operating expense management.
- Total net sales fell 6.7% to $64.9 million, missing prior-year growth as device placements dropped 8.3% to 746 units and consumables revenue declined 6.1% to $46.4 million.
- Full-year revenue guidance was cut to $280 million to $295 million from $285 million to $305 million, reflecting persistent softness in capital equipment demand and the time required for commercial fixes to take effect.
- +7 more takeaways
Good Times Restaurants Inc. Q2 Fiscal 2026 Earnings Call - Costs Drop, Loyalty Surges, and a $2 Burger Test
Good Times Restaurants Inc. delivered a cleaner balance sheet and tighter margins in fiscal Q2 2026, driven by disciplined cost management and a loyalty program that nearly doubled its sales contribut...
- Total revenues fell 3.1% year-over-year to $33.2 million, reflecting lower guest traffic at Bad Daddy’s and a closed unit.
- Same-store sales declined 0.8% at both Bad Daddy’s and Good Times, but the pace of decline improved sequentially from Q1.
- Bad Daddy’s restaurant-level operating profit held flat at $3.3 million (13.8% of sales), while Good Times profit rose to $0.9 million (10.1% of sales), a 150 basis point margin expansion.
- +7 more takeaways
SIGA Technologies Q1 2026 Earnings Call - Q1 Results Lumpy but Balance Sheet Buys Time for Government Deals
SIGA Technologies reported a lumpy first quarter with minimal product deliveries, yet the balance sheet remains fortified with $146 million in cash and no debt, prompting a $0.60 per share special div...
- Q1 2026 product revenues were minimal, driven by the inherent lumpy rhythm of government procurement and international sales cycles.
- Management guided for approximately $13 million in oral TPOXX deliveries to an international customer in Q2 2026, alongside additional IV TPOXX deliveries to the U.S. Strategic National Stockpile (SNS).
- SIGA maintains a fortress balance sheet with $146 million in cash and zero debt as of March 31, 2026, providing substantial liquidity to navigate contracting delays.
- +7 more takeaways
Pulse Biosciences Q1 2026 Earnings Call - Enrolls First U.S. Patients in Pivotal Atrial Fibrillation Trial Amid Strategic Realignment
Pulse Biosciences delivered a defining first quarter for 2026, marked by the commencement of enrollment in its U.S. IDE pivotal trial (NANOPULSE-AF) for the nPulse cardiac catheter system and a strate...
- Pulse Biosciences commenced enrollment in its U.S. IDE pivotal study (NANOPULSE-AF) for the nPulse cardiac catheter system in early April 2026, marking a critical inflection point for its atrial fibrillation program.
- Landmark late-breaking data from the European feasibility study presented at Heart Rhythm 2026 showed 100% procedural success at 6 months and 90% Kaplan-Meier estimated freedom from recurrent arrhythmias at 1 year, reinforcing the durability of nsPFA technology.
- Management announced a strategic realignment to prioritize the nPulse cardiac catheter program, reallocating resources to accelerate clinical development, regulatory filings, and commercialization efforts.
- +7 more takeaways
Nephros, Inc. Q1 2026 Earnings Call - Revenue Hits Record $5.2M Amid Margin Compression and Strategic Expansion
Nephros delivered a milestone first quarter, posting record revenue of $5.2 million and surpassing the $5 million threshold for the first time. The growth was driven by a 23% year-over-year increase i...
- Record Revenue Milestone: Nephros reported first-quarter revenue of $5.2 million, marking the first time the company has surpassed the $5 million quarterly threshold. This performance reflects strong execution across core business lines and expanding adoption of new product applications.
- Programmatic Growth Outpaces Overall Growth: Programmatic revenue grew 23% year-over-year, serving as the primary driver of the company's top-line expansion. This metric underscores the health of the underlying business model, as customers are actively installing, reordering, and expanding usage over time.
- Margin Compression Driven by External Factors: Gross margins fell to 57% from 65% in the prior year quarter. Management attributed the decline to a $200,000 tariff headwind, currency pressures from a strengthening euro, and a strategic shift toward lower-margin commercial applications.
- +7 more takeaways
Ginkgo Bioworks Q1 2026 Earnings Call - Autonomous Lab Strategy Takes Center Stage
Ginkgo Bioworks Q1 2026 earnings call centered on a strategic pivot toward autonomous laboratories, with CEO Jason Kelly outlining plans to scale its Nebula system to over 100 Reconfigurable Automatio...
- Ginkgo Biowinks Q1 2026 revenue was $19 million, down 49% year-over-year, with a $7.5 million non-cash item from the BiomEdit termination excluded from the comparison.
- Cash burn decreased 17% to $48 million in Q1 2026, down from $58 million in Q1 2025, reflecting restructuring efforts and cost discipline.
- The company holds $373 million in cash with zero bank debt, providing a strong balance sheet to fund its autonomous lab strategy.
- +7 more takeaways
PacBio Q1 2026 Earnings Call - Record Consumables Revenue Offsets Vega Funding Headwinds
PacBio reported flat top-line revenue in Q1 2026, but the underlying dynamics tell a sharper story. Consumable revenue hit a record $21.8 million, driven by clinical accounts that grew over 100% year-...
- Total revenue was flat year-over-year at $37.2 million, reflecting a tug-of-war between strong consumable growth and softer instrument demand.
- Consumable revenue reached a record $21.8 million, a 9% increase, with clinical shipments growing over 100% year-over-year.
- Instrument revenue fell 12% to $9.7 million, dragged down by lower average selling prices on the Vega platform and a promotional discount.
- +7 more takeaways
Natural Grocers by Vitamin Cottage Q2 FY2026 Earnings Call - Comps Miss, ERP Upgrade Complete, Guidance Tightens
Natural Grocers delivered a mixed second quarter, with comparable store sales ticking up just 0.5% against a 8.9% surge a year ago. The number tells a story of consumer fatigue. Basket size grew 1.6%,...
- Comparable store sales grew just 0.5%, a sharp deceleration from 8.9% a year ago, signaling consumer fatigue in a value-seeking environment.
- Daily average comps were driven by a 1.6% increase in basket size, while transaction counts declined 1.1%, showing shoppers buying more per trip but visiting less often.
- nPower Rewards membership penetration surged 300 basis points to 84%, proving the loyalty program is the core engine of revenue and a critical buffer against economic uncertainty.
- +9 more takeaways
ICU Medical Q1 2026 Earnings Call - Core Businesses Grow as Tariff Headwinds Offset by Efficiency Gains
ICU Medical delivered a mixed Q1 2026 report where organic growth remained steady despite macroeconomic noise. Revenue came in at $526 million, up 1% organically but down 12% reported due to the decon...
- Total revenue was $526 million, reflecting 1% organic growth but a 12% reported decline due to the deconsolidation of the IV Solutions business into an Otsuka joint venture.
- Adjusted gross margins expanded to 41%, beating expectations, driven by favorable product mix and the exit of lower-margin business segments.
- Adjusted EBITDA held steady at $99 million year-over-year, while adjusted EPS rose 15% to $1.97, supported by cost discipline and mix improvement.
- +7 more takeaways
Xponential Fitness Q1 2026 Earnings Call - Same-Store Sales Dip 6% Amid Digital Ad Shifts, But Management Reaffirms 2026 Guidance and Highlights Retention Strength
Xponential Fitness reported a 6% decline in Q1 2026 same-store studio sales, driven by a tough year-over-year comparison and structural headwinds in digital advertising. Meta’s transition to an AI-dri...
- Same-store studio sales declined 6% overall in Q1 2026, with Club Pilates down 4%, against a tough 9% growth comparison from Q1 2025.
- Member retention improved 36 basis points year-over-year, marking the best retention month since Q1 2024, with Club Pilates 3-year LTV exceeding $2,300.
- Digital advertising headwinds from Meta’s AI-driven Andromeda platform and Google’s AI-generated search results reduced organic traffic and lead flow.
- +7 more takeaways